Protease Formulation for C. Difficile Toxin Degradation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Clostridioides difficile infection (CDI), such as antibiotics and fecal transplants, have high failure rates and are labor-intensive, posing significant health challenges and outbreaks, especially in healthcare settings.
Innovation Solution
Administration of a therapeutically effective amount of HTRA or HTRA-NS protein to degrade Clostridioides difficile toxins TcdA, TcdB, and CDT, restoring gastrointestinal flora and preventing disease progression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibiotics are used to treat C. difficile infection, then bacterial growth is inhibited, but treatment failure rate increases and contributes to outbreaks
Solution Approach 1:
The patent converts the harmful effect of antibiotics (which kill beneficial gut bacteria and enable C. difficile overgrowth) into a beneficial treatment approach by using proteases to specifically target and degrade C. difficile toxins without affecting the broader microbiome. This selective toxin degradation eliminates the harmful effects of antibiotic use while maintaining gut flora balance.
Solution Approach 2:
The patent introduces proteases as intermediary agents that mediate between the host and C. difficile toxins. Rather than directly killing bacteria (antibiotics) or introducing foreign microbiota (fecal transplant), proteases act as a molecular mediator that neutralizes toxins by degrading their protein structures, providing a bridge solution that avoids the drawbacks of current treatments.
2Reliability
If fecal transplants are used to recolonize the gut, then CDI resolves in many cases, but the process becomes labor intensive and requires intensive screening
Solution Approach 1:
The patent extracts the essential therapeutic function of fecal transplants (restoring gut microbiota balance and resolving CDI) while eliminating the cumbersome aspects (donor screening, labor-intensive procedures). By identifying and isolating specific proteases that mediate the protective effect against toxins, the treatment delivers the beneficial outcome through a simplified, standardized protein therapy rather than complex biological material transfer.
Solution Approach 2:
The patent creates a simplified copy or surrogate of the fecal transplant mechanism by using purified proteases that replicate the toxin-neutralizing function. Instead of transferring complex microbial communities, the invention uses defined protease proteins that copy the essential protective action, making the treatment more controllable and less labor-intensive while maintaining effectiveness.
3Object-affected harmful factors
If proteases are used to degrade toxins, then toxin neutralization occurs, but protease stability and activity must be maintained in the gastrointestinal environment
Solution Approach 1:
The patent applies parameter changes to optimize protease function in the gastrointestinal environment. By modifying protease properties such as pH stability, temperature resistance, and proteolytic resistance through enzyme selection or engineering, the treatment maintains protease activity despite the harsh GI conditions including low pH, enzymes, and varying temperatures.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The HTRA or HTRA-NS protein effectively neutralizes CD toxins, reducing symptoms and recurrence, maintaining gut health, and providing a 10-fold survival benefit in mouse models, with no significant weight loss or microbiota disruption.
Implementation Method 1
HTRA or HTRA-NS protein effectively neutralizes CD toxins
Data Source
AI summary
A method for treatment of one or more toxin(s) in a subject, that includes administering to the subject a therapeutically effective amount of a serine protease that enzymatically cleaves certain toxins. Also, a method for preventing disease progression in a subject infected by Clostridioides difficile (CD), diarrhea, or infectious colitis, which includes administering to the subject a therapeutically effective amount of the protease. The protease retains its activity up to 65° C. Treatment with the protease in mice infected with CD conferred a 10-fold survival benefit compared to mice infected with CD and untreated.